The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a huge mover today! About 1.33 million shares traded hands or 48.01% up from the average. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 3.75% since April 5, 2016 and is downtrending. It has underperformed by 5.70% the S&P500.
The move comes after 7 months positive chart setup for the $3.90B company. It was reported on Nov, 7 by Barchart.com. We have $55.33 PT which if reached, will make NASDAQ:NBIX worth $975.00 million more.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage
Out of 7 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Neurocrine Biosci has been the topic of 7 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Leerink Swann maintained the stock with “Outperform” rating in Monday, October 12 report. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, June 29. The rating was initiated by Needham with “Buy” on Tuesday, October 18. The firm earned “Buy” rating on Tuesday, August 18 by Jefferies. BMO Capital Markets initiated Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Thursday, April 7 with “Outperform” rating. The firm has “Overweight” rating by Piper Jaffray given on Thursday, October 8. Deutsche Bank initiated the stock with “Buy” rating in Thursday, November 3 report.
According to Zacks Investment Research, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.”
Insitutional Activity: The institutional sentiment decreased to 0.89 in 2016 Q2. Its down 0.21, from 1.1 in 2016Q1. The ratio dropped, as 18 funds sold all Neurocrine Biosciences, Inc. shares owned while 89 reduced positions. 37 funds bought stakes while 58 increased positions. They now own 83.14 million shares or 3.77% less from 86.40 million shares in 2016Q1.
Wexford Ltd Partnership owns 27,020 shares or 0.21% of their US portfolio. Birchview Cap Limited Partnership last reported 25,200 shares in the company. De Burlo Grp has 52,450 shares for 0.58% of their US portfolio. Quantitative Invest Mngmt Llc reported 16,600 shares or 0.04% of all its holdings. The Colorado-based Alps Advsr has invested 0.05% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Schwab Charles Invest accumulated 254,576 shares or 0.01% of the stock. Blackrock Japan Com has invested 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Nuveen Asset Management Limited Liability has 0% invested in the company for 10,964 shares. Senator Invest Ltd Partnership has invested 0.62% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Utah Retirement last reported 15,600 shares in the company. The New York-based Millennium Management Ltd Com has invested 0.06% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Ridgeworth Cap Llc last reported 11,970 shares in the company. Clarivest Asset Management Limited Liability last reported 0.05% of its portfolio in the stock. Diam Com, a Japan-based fund reported 170,367 shares. Timessquare Capital Mngmt Limited accumulated 0.13% or 437,300 shares.
Insider Transactions: Since May 16, 2016, the stock had 0 buys, and 7 insider sales for $4.20 million net activity. 5,000 shares with value of $242,700 were sold by Nevinny Corinne H on Monday, August 8. Shares for $625,000 were sold by OBrien Christopher Flint on Tuesday, May 31. 9,000 shares with value of $450,000 were sold by Lloyd-Smith Malcolm on Tuesday, May 31. $700,800 worth of shares were sold by POPS RICHARD F on Wednesday, May 25.
More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Prnewswire.com which released: “Neurocrine Biosciences to Present at the Credit Suisse 25th Annual Healthcare …” on October 31, 2016, also Prnewswire.com with their article: “Neurocrine Biosciences Announces Conference Call and Webcast to Report Third …” published on October 26, 2016, Prnewswire.com published: “Neurocrine Biosciences Reports Third Quarter 2016 Results” on November 02, 2016. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Seekingalpha.com and their article: “Neurocrine Biosciences’ First Product Approval On The Line” published on November 01, 2016 as well as Fool.com‘s news article titled: “Why Neurocrine Biosciences Inc.’s Stock Skyrocketed 147% Higher in 2015” with publication date: January 14, 2016.
NBIX Company Profile
Neurocrine Biosciences, Inc., incorporated on March 20, 1996, is engaged in the development of pharmaceutical products focused on neurological and endocrine diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Firm focuses on developing NBI-640756 against Essential tremor. The Company’s research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.